Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares on June 10, 2026 at $231.83 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan and occurred automatically. After this transaction, she directly holds 51,549 ordinary shares. A footnote also notes she acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
JAZZ: A Rule 144 notice lists a broker-facilitated sale and securities effected by the issuer. The filing reports 1,192 shares of Common Stock sold on 05/28/2026 for $282,468.24. It also lists 600 performance shares dated 01/16/2026 and 600 restricted shares dated 03/05/2025.
Jazz Pharmaceuticals plc is asking shareholders to vote at its 2026 annual general meeting on July 23, 2026, in Dublin. Shareholders will elect three directors, ratify KPMG as auditor, approve executive compensation on an advisory basis, and renew key share issuance authorities under Irish law.
The board seeks renewed authority to allot ordinary shares within existing authorized capital and, via a special resolution, to issue shares for cash without pre-emption rights up to 20% of issued share capital for 18 months. A separate proposal would allow adjournment if support for these capital authorities is initially insufficient.
The record date is May 28, 2026, with 62,817,628 ordinary shares entitled to one vote each. The board says 11 of 13 current directors are independent and highlights a classified board, active refreshment, strong committee structure, share ownership guidelines, an annual say‑on‑pay vote, and a Clawback Policy. Non‑employee directors receive cash retainers and annual RSU awards targeted at $400,000.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a charitable share transfer. On June 3, 2026, she made a bona fide gift of 600 ordinary shares at a stated price of $0.00 per share, reducing her direct holdings to 152,196 shares. A footnote also notes that she acquired 166 ordinary shares through a Section 423 Employee Stock Purchase Plan on May 29, 2026, highlighting ongoing participation in employee equity programs.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 Ordinary Shares of JAZZ in an open-market transaction. The shares were sold at an average price of $235.12 per share. After this sale, he directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals.
The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the transaction timing was scheduled in advance and was not a discretionary trade by the reporting person.
Jazz Pharmaceuticals filing a Form 144 notice reporting proposed sales of 6,000 shares on multiple dates by Bruce Cozadd. The excerpt lists transactions dated 05/01/2026, 04/01/2026, and 03/03/2026 each showing 6,000 shares and associated amounts.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported an open-market sale of 1,192 Ordinary Shares at $236.97 per share. After this transaction, she directly holds 52,626 shares.
The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026, indicating it was pre-scheduled rather than a discretionary trade based on short-term market conditions.
Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock. On May 28, 2026, the EVP, Chief Commercial Officer exercised non-qualified stock options to acquire 6,907 ordinary shares at an exercise price of $109.45 per share and sold 6,907 ordinary shares in an open-market transaction at $235.41 per share. Following these transactions, she directly owns 50,272 ordinary shares. The exercised options were granted under the company’s 2011 Equity Incentive Plan and had fully vested by March 2, 2024, and this specific option grant is now fully exercised.
Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share. After this exercise, he holds 1,183,028 Ordinary Shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
The option was originally granted on August 11, 2016 and had fully vested by August 1, 2017. Following this transaction, no shares remain under the exercised option, and there is no remaining derivative position reported in this filing.